Walmsley S - Search Results

1

Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.

Tan D, Walmsley S. Tan D, et al. Among authors: walmsley s. Expert Rev Anti Infect Ther. 2007 Feb;5(1):13-28. doi: 10.1586/14787210.5.1.13. Expert Rev Anti Infect Ther. 2007. PMID: 17266450 Review.

2

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E; M98-863 Study Team. Walmsley S, et al. N Engl J Med. 2002 Jun 27;346(26):2039-46. doi: 10.1056/NEJMoa012354. N Engl J Med. 2002. PMID: 12087139 Free article. Clinical Trial.

3

Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy.

Loutfy M, Raboud J, Thompson C, Tseng A, Abdurrahman Z, Kovacs C, Rachlis A, Phillips E, Rubin G, Gough K, Walmsley S. Loutfy M, et al. Among authors: walmsley s. HIV Clin Trials. 2003 Sep-Oct;4(5):301-10. doi: 10.1310/7LYW-GQFF-WPRQ-K3QW. HIV Clin Trials. 2003. PMID: 14583846

4

The role of lopinavir/ritonavir (Kaletra) in the management of HIV infected adults.

Walmsley S, Christian MD. Walmsley S, et al. Expert Rev Anti Infect Ther. 2003 Oct;1(3):389-401. doi: 10.1586/14787210.1.3.389. Expert Rev Anti Infect Ther. 2003. PMID: 15482136 Review.

5

Mild to moderate symptoms do not correlate with lactate levels in HIV-positive patients on nucleoside reverse transcriptase inhibitors.

Tan D, Walmsley S, Shen S, Raboud J. Tan D, et al. Among authors: walmsley s. HIV Clin Trials. 2006 May-Jun;7(3):107-15. doi: 10.1310/95VE-A6KJ-WRQ0-1F8Y. HIV Clin Trials. 2006. PMID: 16880167 Clinical Trial.

6

Protease inhibitor-based regimens for HIV therapy: safety and efficacy.

Walmsley S. Walmsley S. J Acquir Immune Defic Syndr. 2007 Jun 1;45 Suppl 1:S5-13; quiz S28-31. doi: 10.1097/QAI.0b013e3180600709. J Acquir Immune Defic Syndr. 2007. PMID: 17525691 Review.

7

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.

Walmsley S, Avihingsanon A, Slim J, Ward DJ, Ruxrungtham K, Brunetta J, Bredeek UF, Jayaweera D, Guittari CJ, Larson P, Schutz M, Raffi F. Walmsley S, et al. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):367-74. doi: 10.1097/QAI.0b013e318198a815. J Acquir Immune Defic Syndr. 2009. PMID: 19214123 Clinical Trial.

8

Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.

Tan DH, Chan K, Raboud J, Cooper C, Montaner JS, Walmsley S, Hogg RS, Klein MB, Machouf N, Rourke SB, Tsoukas C, Loutfy MR; CANOC Collaboration. Tan DH, et al. Among authors: walmsley s. J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):38-46. doi: 10.1097/QAI.0b013e3182282cfc. J Acquir Immune Defic Syndr. 2011. PMID: 21709570

9

A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.

Yi TJ, Walmsley S, Szadkowski L, Raboud J, Rajwans N, Shannon B, Kumar S, Kain KC, Kaul R, Tan DH. Yi TJ, et al. Among authors: walmsley s. Clin Infect Dis. 2013 Nov;57(9):1331-8. doi: 10.1093/cid/cit539. Epub 2013 Aug 14. Clin Infect Dis. 2013. PMID: 23946220 Clinical Trial.

10

Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies.

Tan DH, Murphy K, Shah P, Walmsley SL. Tan DH, et al. BMC Infect Dis. 2013 Oct 28;13:502. doi: 10.1186/1471-2334-13-502. BMC Infect Dis. 2013. PMID: 24164861 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

598 results

Search Page